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OBJECTIVES: The secretin-stimulated endoscopic pancreatic function test (ePFT) allows for the safe collection of
gastroduodenal and pancreatic ﬂuid from the duodenum. We test the hypothesis that these endoscopically collected ﬂuids
have different proteomes. As such, we aim to show that the ePFT method can be used to collect ﬂuid enriched in pancreatic
proteins to test for pancreatic function.
METHODS: Gastroduodenal and pancreatic ﬂuid were collected sequentially from chronic pancreatitis patients undergoing an
ePFT.ProteinsfromeachﬂuidtypewereextractedusingpreviouslypublishedoptimizedmethodsandsubjectedtoGeLC-MS/MS
analysis for protein identiﬁcation and bioinformatics analysis.
RESULTS: Mass spectrometry analysis identiﬁed proteins that were exclusive in either gastroduodenal (46) or pancreatic ﬂuid (234).
Subsequent quantitative analysis revealed proteins that were differentially abundant with statistical signiﬁcance. As expected,
proteolytic enzymes and protease inhibitors were among the differentially detected proteins. The proteases pepsinogens and gastrin
were enriched in gastroduodenal ﬂuid, while common pancreatic enzymes (e.g., aminopeptidase N, chymotrypsin C, elastase-3A,
trypsin, and carboxypeptidase A1, and elastase 2B) were found in greater abundance in pancreatic ﬂuid. Similarly for protease
i n h i b i t o r s ,m e m b e r so ft h ec y s t a t i nf a m i l yw e r ee x c l u s i v et og astroduodenal ﬂuid, while serpins A11, B4, and D1 were exclusive to
pancreatic ﬂuid.
CONCLUSIONS: We have shown that ePFT collection coupled with mass spectrometry can be used to identify differentially detected
proteinsingastroduodenalandpancreaticﬂuids.ThedataobtainedusingGeLC-MS/MStechniquesprovidefurtherevidencesupporting
the feasibility of using ePFT-collected ﬂuid to study speciﬁc diseases of the upper gastrointestinal tract, such as chronic pancreatitis.
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INTRODUCTION
Diseases of the upper gastrointestinal tract are major burdens
on the healthcare system. In the United States alone, over
22000 new cases of gastric cancer were diagnosed and over
11000 gastric cancer-related deaths were reported in 2006.
1
Nationally, the ﬁnancial cost of gastric cancer in 2010 is
estimated to be more than $1.8 billion.
2 Similarly, disorders of
the pancreas affect more than 1 million persons in the United
States and cost nearly $3 billion annually. Over the past
decade, pancreatic diseases have resulted in 277000
hospitalizations and 475000 annual ambulatory care visits,
of which nearly 25% are because of chronic pancreatitis.
3
Novel methods are needed to enable the diagnosis of early
disease and to understand better the pathogenesis of the
disease. Proteomic experiments directed toward the study of
gastroduodenal and pancreatic disease present a unique
opportunity to accelerate the pace of disease-speciﬁc
biomarker discovery.
Although tissue biopsies are often utilized forscreening and
diagnosis of gastrointestinal diseases, such methods are
invasive, may result in infections and complications, and only
sample a small region of the tissue being investigated,
potentially missing the diseased region. Proximal body ﬂuids,
however,bathethediseasedorganandrepresenttheproteins
in the nearby tissue.
4 In contrast, the proteins in systemic
body ﬂuids, such as urine, blood, and its derivatives (i.e.,
plasma or serum), correlate to the entire body and likely
include those not related to the disease of interest. Further-
more, disease-speciﬁc markers that are secreted or shed
directly into proximal ﬂuids are likely to be present in a higher
concentration than in blood or urine, as no dilution or ﬁltration
has occurred.
The endoscopic pancreatic function test (ePFT) allows for
thesafecollectionofgastroduodenalandpancreaticﬂuidfrom
the duodenum. During this test, pancreatic secretion is
typically stimulated by secretin, which acts on pancreatic duct
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5,6 Stimulation of these duct cells by secretin
results in secretion of bicarbonate-enriched ﬂuid, which
facilitates excretion of proteins. This ﬂuid is readily and safely
collected endoscopically and can be used for mass spectro-
metry-based proteomic analysis.
7,8
Pancreatic and gastroduodenal ﬂuid are excellent clinical
specimens for the identiﬁcation of disease-speciﬁc biomar-
kers by proteomic analysis, as each is a proximal ﬂuid of
relatively low complexity, thereby facilitating the identiﬁcation
of low-abundant proteins.
9–11 The application of body ﬂuid
proteomics in the study of pancreatic and gastroduodenal
disease may reveal physiologically and clinically relevant
markers of disease.
12,13 Gastroduodenal and pancreatic ﬂuid
areproximalbodyﬂuidsofthedigestivesystemhavingrolesin
protein digestion, and therefore are expected to be rich in
digestive proteins. Moreover, many gastric and pancreatic
diseases are exacerbated by adverse proteolytic events. As
such,weexpecttodiscoverdifferencesinsecretedproteolytic
enzymes and protease inhibitors between the two ﬂuids.
Further knowledge of the underlying molecular events
affecting proteolytic dysregulation will have a positive impact
on the understanding of the natural history of upper gastro-
intestinal tract diseases.
Using our previously optimized methods of sample pre-
paration for gastroduodenal
14 and pancreatic ﬂuid,
15,16 and
mass spectrometry-based protein identiﬁcation, we present a
comparative proteomic analysis of these ePFT-collected ﬂuid
samples. We aim to show that ePFT-collected gastroduo-
denal and secretin-stimulated pancreatic ﬂuids have different
proteomes. As such, it would follow that the ePFT method can
beusedtocollectsecretin-stimulatedﬂuidenrichedinproteins
of pancreatic origin to test for pancreatic function.
To achieve our aims, we will (1) collect gastroduodenal and
pancreatic ﬂuids from each subject, (2) extract proteins from
gastroduodenal and pancreatic ﬂuids using our previously
optimized methods, (3) perform GeLC-MS/MS analysis,
(4) identify proteins using Mascot (Matrix Science, Boston,
MA, USA) and ProteomeDiscoverer software (Thermo Fisher
Scientiﬁc, Waltham, MA, USA), and (5) compare identiﬁed
proteins using qualitative (Scaffold3) and quantitative
(QSPEC) bioinformatic techniques.
METHODS
Materials. ChiRhoStim synthetic human secretin was from
ChiRhoClin (Burtonsville, MD, USA). SeeBluePlus2 Pre-
Stained standard (LC5925), lithium dodecyl sulfate sample
buffer (NP0008), NuPAGE 4–12% Bis-Tris polyacrylamide
gels (NP0335), Simply Blue Coomassie stain (LC0665), and
MES-SDS (2-(N-morpholino) ethanesulfonic acid-sodium
dodecyl sulfate) running buffer (NP002) were from Invitrogen
(Carlsbad, CA, USA). Other reagents and solvents were from
Sigma-Aldrich (St Louis, MO, USA) and Burdick and Jackson
(Muskegon, MI, USA), respectively.
Study cohort. This protocol was approved by the
Institutional Review Board at Brigham and Women’s
Hospital (IRB 2007-P-002480/1). The study cohort included
adult patients seen in the Center for Pancreatic Diseases at
Brigham and Women’s Hospital. Subjects were referred for
evaluation of pancreatic etiologies for their gastrointestinal
symptoms. All subjects underwent the following: (1) compre-
hensive history and physical examination, (2) review of
radiological and endoscopic data, and (3) upper endoscopy
with ePFT followed by mucosal biopsy. The diagnosis of
chronic pancreatitis was determined using the M-ANNHEIM
(Multiple risk factors, Alcohol, Nicotine, Nutrition, Hereditary
factors, Efferent duct factors, Immunological factors, and
Miscellaneous and metabolic factors) classiﬁcation.
17 The
M-ANNHEIM classiﬁcation is a standardized system designed
to classify chronic pancreatitis according to etiology, clinical
staging, and severity of the disease.
17 This system considered
clinical data from a wide array of laboratory tests, and radio-
logical imaging techniques including ultrasound, endoscopic
ultrasound, magnetic resonance imaging, computed tomo-
graphy, as well as risk factors of chronic pancreatitis.
17,18 The
study cohort (Table 1) was comprised of three subjects
classiﬁed as ‘‘Deﬁnite Chronic Pancreatitis,’’ according to the
M-ANNHEIM classiﬁcation system.
Experimental workﬂow. Figure 1 illustrates the general
workﬂow for the overall analysis as follows: (1) collect
gastroduodenal and pancreatic ﬂuids from each subject, (2)
extract proteins from gastroduodenal and pancreatic ﬂuids
using our previously optimized methods,
12,14,16 (3) perform
GeLC-MS/MS analysis, (4) identify proteins using Mascot
and ProteomeDiscoverer software, and (5) compare identi-
ﬁed proteins using qualitative (Scaffold3) and quantitative
(QSPEC) bioinformatic techniques.
Gastroduodenal and pancreatic ﬂuid collection (ePFT
method). The ePFT procedure was performed as previously
described.
7 Gastroduodenal ﬂuid was collected immediately
before secretin stimulation.
14 Pancreatic ﬂuid that was used
for the ensuing analysis was collected at the 30-min time
point following secretin stimulation, as was previously
published.
15 Protein concentration was determined using
the bicinchoninic acid protein assay.
19
Protein precipitation. We have previously compared a
series of protein precipitation procedures, establishing
that proteins from gastroduodenal and pancreatic ﬂuid were
most efﬁciently extracted by acetone and trichloroacetic acid
(TCA), respectively.
14,16 Although we used different methods
of precipitation, it was our intention to maximize the proteins
identiﬁed via our previously optimized protocols. These
precipitation processes limit protein degradation by instan-
taneously deactivating enzymes, concentrating the protein
sample, and removing salts that will interfere with the
subsequent electrophoretic mobility-based fractionation by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), as described below.
Acetone precipitation of gastroduodenal ﬂuid. Four sample
volumes (800ml) of ice-cold 100% acetone were added
to 200ml of gastroduodenal ﬂuid, vortexed brieﬂy, and
incubated at  201C for 3h. Subsequently, the samples
were centrifuged at 20000  g at 41C for 30min. The super-
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to air dry at 231C.
TCA precipitation of pancreatic ﬂuid. Aliquots of pancreatic
ﬂuid samples for proteomic analysis were collected on ice (as
described above), centrifuged at 41C at 14000r.p.m. for
15min to remove cellular debris, and aliquoted (500ml)
before storage at  801C. Ice-cold 100% TCA (25ml) was
added to 200ml of pancreatic ﬂuid, vortexed, and incubated
at 41C for 2h. The sample was centrifuged at 20000  g at
41C for 30min and the supernatant was carefully aspirated.
One milliliter of 100% ice-cold acetone was added to the
pellets, which were brieﬂy vortexed and incubated at  201C
for 1h. The sample was centrifuged at 20000  g at 41C for
30min and the pellet was washed twice with 100% ice-cold
acetone. The ﬁnal pellets were allowed to air dry at room
temperature.
SDS-PAGE prefractionation and liquid chromatography-
tandem mass spectrometry (GeLC-MS/MS) of gastroduo-
denal pancreatic ﬂuid specimens. Protein concentration
was determined using the BioRAD protein assay according to
the manufacturer’s instructions, so that B100mg of protein
was loaded per gel lane. Each precipitated protein pellet
was re-dissolved in 50ml of reducing Laemmli buffer
20
(with 10mM DTT) for 1h at 561C and alkylated with 1%
acrylamide at room temperature for 30min for subsequent
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Figure 1 General workﬂow. (1) As part of the standard endoscopic pancreatic
function test (ePFT) procedure, gastroduodenal ﬂuid is collected from the
duodenum before secretin injection. In addition, we collected a pancreatic ﬂuid
sample 30min after secretin stimulation. (2) Protein was extracted using acetone
precipitation for gastroduodenal ﬂuid and trichloroacetic acid (TCA) precipitation for
pancreatic ﬂuid. (3) Following precipitation, proteins from each sample were
fractionated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and gel lanes were subsequently processed via standard GeLC-MS/MS
methods. (4) Database searching was performed via the ProteomeDiscoverer
graphical user interface with Mascot database searching. (5) Data were analyzed
furtherusingScaffold3forqualitativecomparisonandQSPECtoidentifystatistically
signiﬁcant quantitative differences. GDF, gastroduodenal ﬂuid; PF, pancreatic ﬂuid.
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Clinical and Translational GastroenterologyGeLC-MS/MS analysis. The proteins were fractionated on
4–12% NuPAGE pre-cast SDS-PAGE gels at 175V for
45min using MES-SDS running buffer. Subsequently, each
gel lane was divided into 10 sections. Proteins in each gel
section were digested in-gel with trypsin.
21,22 The extracted
peptides from each gel section were subjected to peptide
fractionation using reversed-phase high performance liquid
chromatography (Thermo Scientiﬁc, Waltham, MA, USA) and
the gradient-eluted peptides were analyzed by a hyphenated
LTQ-FTICR (linear trap quadrupole-Fourier Transform ion
cyclotron resonance) mass spectrometer (Thermo Scientiﬁc).
The liquid chromatography columns (15cm 100mm ID)
were packed in-house (Magic C18, 5mm, 100A ˚ beads,
Michrom BioResources, into PicoTips, New Objective,
Woburn, MA, USA). Samples were analyzed with a 60-min
linear gradient (5–35% acetonitrile with 0.2% formic acid) and
data were acquired in a data-dependent manner, in which
MS/MS fragmentation was performed using the six most
intense peaks of every full MS scan.
Bioinformatics and data analysis
Database search. All data generated from the gel sections
were searched against the international protein index number-
human database (v3.69) using the Mascot search engine
(v.2.204; Matrix Science, Boston, MA, USA) through the
ProteomeDiscoverer graphical user interface (v 1.2; Thermo
Fisher Scientiﬁc). One miscleavage per peptide was allowed
and mass tolerances of±10p.p.m. for precursor and
of±0.8Da for fragment ions were used. Amino-acid modi-
ﬁcations: ﬁxed: propionamide (Cys); variable: deamidation
(Asn/Gln), pyro-glutamate (N-terminal Glu/Gln), and oxidation
(Met). Our false discovery rate was determined by searching
the same dataset against the target database and a decoy
database; the latter featured the reversed amino-acid
sequences of all the entries in the international protein index
human database (v3.69).
23,24
Scaffold. Scaffold (version Scaffold 3.00.07, Proteome
Software, Portland, OR, USA) was used to validate
MS/MS-based peptide and protein identiﬁcations. Peptide
identiﬁcations were accepted if they could be established at
495% probability as speciﬁed by the Peptide Prophet
algorithm.
25 Protein identiﬁcations were accepted if they
could be established at greater than 99% probability and
contained at least one identiﬁed peptide. Protein probabilities
were assigned by the Protein Prophet algorithm.
26 Proteins
that contained similar peptides and could not be differen-
tiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony.
Spectral counting. Relative protein quantitation was accom-
plished using a label-free technique, spectral counting, which
compared the number of identiﬁed tandem mass spectra for
the same protein across multiple data sets. To search for
differences in the protein proﬁle among data sets, spectral
counts were normalized based on the total spectral counts,
as previously suggested.
27 Speciﬁcally, spectral counts of
each protein were divided ﬁrst by the total spectral counts
of all proteins from the same sample, and then multiplied by
the total spectral counts of the sample with the maximum
total number of spectral counts. Signiﬁcance analysis of
our spectral count data was performed using QSPEC, a
recently published algorithm for determining the statistical
signiﬁcance of differences in spectral counting data from two
sample sets.
28 This algorithm uses the Bayes factor, in lieu of
the P value, as a measure of statistical signiﬁcance.
29,30
According to convention, a Bayes factor 4 10 suggests
strong evidence (analogous to a type-I error of ao0.05) that
a particular protein was differentially detected with statistical
signiﬁcance between the two cell states, thus a value of 10
was used as our signiﬁcance threshold.
31
Results
Gastroduodenal and pancreatic ﬂuid were collected
successfully for proteomic analysis. Gastroduodenal
and pancreatic ﬂuid from three patients were collected safely
with a sterile trap in-line with the vacuum. Table 1 lists the
volumes and protein concentrations (as estimated using the
bicinchoninic acid assay) of the collected ﬂuids. For pancreatic
ﬂuid, the mean volume was 5.4±1.0ml, while the mean protein
concentration was 0.8±0.3mg/ml. Similarly, for gastroduodenal
ﬂuid, the mean volume was 2.3±0.9ml, while the mean protein
concentration was 1.7±0.4mg/ml. Samples were stored on ice
and centrifuged (3000  g for 15min at 41C) within 30min of
collection. The collected supernatants were frozen at  801C
until proteins were extracted for SDS-PAGE analysis.
SDS-PAGE analysis revealed characteristic protein
patterns. In agreement with what we have published
previously, the protein patterns as illustrated by SDS-PAGE
imaging differed substantially between gastroduodenal ﬂuid
(Figure 2a) and pancreatic ﬂuid (Figure 2b). In addition, when
comparing inter-ﬂuid variation, fewer protein bands were
present in gastroduodenal ﬂuid samples compared with
samples from pancreatic ﬂuid. Analogous differences in the
number of proteins were determined in subsequent mass
spectrometry-based protein identiﬁcations. Also, when com-
paring samples within a ﬂuid type, the protein patterns were
similar, but inter-patient variations were visible when com-
paring the protein banding patterns within both the gastro-
duodenal and pancreatic ﬂuid sample sets.
Qualitative comparative mass spectrometry data ana-
lysis identiﬁed proteins that were exclusive to
gastroduodenal or pancreatic ﬂuid. Using our mass
spectrometry-based strategy in which a non-redundant list
of proteins were determined using the Scaffold3 software, we
identiﬁed a total of 285 proteins in gastroduodenal ﬂuid and
473 proteins in pancreatic ﬂuid (Figure 3). Of these proteins,
46 (Supplementary Table 1) were determined to be exclusive
to gastroduodenal ﬂuid and 234 (Supplementary Table 2)
were determined to be exclusive to pancreatic ﬂuid. Proteins
common to both the gastroduodenal and pancreatic ﬂuid
samples (239) were analyzed further by QSPEC to
determine proteins that were not exclusive to either ﬂuid,
but were of enriched in one ﬂuid or the other. In Table 2 we
summarized the protein identiﬁcation data. In addition,
Supplementary Figure 1 illustrates the differences in the
Proteomics of ePFTcollected ﬂuids
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duodenal ﬂuid for each subject.
Quantitative comparative mass spectrometry data
analysis using QSPEC identiﬁed proteins with statis-
tically signiﬁcant enrichment in either gastroduodenal
or pancreatic ﬂuid. We performed QSPEC analysis of the
spectral count values for the 239 proteins that were common
to both gastroduodenal and pancreatic ﬂuid to determine
statistically signiﬁcant differences between the two ﬂuids.
QSPEC was recently published as a Bayesian statistics-
based algorithm for determining the statistical signiﬁcance of
differences in spectral counting data from two sample sets—
in our case, gastroduodenal and pancreatic ﬂuid.
28 This
analysis revealed 41 proteins enriched in gastroduodenal
ﬂuid (Supplementary Table 3) and 67 proteins enriched in
pancreatic ﬂuid (Supplementary Table 4) according to
Bayesian statistical methods.
We deﬁned‘‘differentiallydetectedproteins’’asthoseeither
exclusive to or of statistically signiﬁcant enrichment in one
ﬂuid relative to the other. As such, we have identiﬁed a total of
87 differentially detected proteins (46 exclusive plus 41
enriched) in gastroduodenal ﬂuid (Table 2). Likewise, we
have identiﬁed a total of 301 differentially detected proteins
(234 exclusive plus 67 enriched) in pancreatic ﬂuid (Table 2).
The differentially detected proteins were used for subsequent
gene ontology analysis.
Gene ontology analysis of differentially detected
proteins using Scaffold3 detected differences in
localization and protein function. Using Scaffold3, we
investigated the molecular function of the differentially
detected proteins (Figure 4). We noted that a large
percentage of the proteins identiﬁed from both ﬂuids were
classiﬁed as binding, catalytic, and enzyme regulators. The
binding category is very broad and includes ion, protein, lipid,
nucleotide, carbohydrate, and oxygen binding. As such, it is
expected that this category would be relatively large. The
catalytic and enzyme regulator categories were of particular
interest in regard to proteases and protease inhibitors related
to digestion. Table 3 lists proteases that were exclusive to a
particular ﬂuid, while Table 4 lists those proteases that were
enriched, to a statistically signiﬁcant degree, in a particular
ﬂuid. Similarly, for the identiﬁed protease inhibitors, Table 5
lists those that were exclusive to a particular ﬂuid, whereas
Table 6 lists those that were enriched in a particular ﬂuid.
Discussion
We have shown that the ePFT collection method coupled with
mass spectrometry can characterize proteins in gastroduo-
denal and pancreatic ﬂuids. Our analysis revealed the
presence of proteases and protease inhibitors that are
enriched in either gastroduodenal or pancreatic ﬂuid. We
determined that (1) gastroduodenal and pancreatic ﬂuid can
be sequentially collected from the same patient, (2) proteins
can be readily extracted by ﬂuid-speciﬁc chemical precipita-
tion methods, and (3) proteases and enzyme regulators
comprise the major protein functions, as determined by
gene ontology annotation, for both gastroduodenal and
pancreatic ﬂuid.
Proteomic investigations of human body ﬂuids for clinical
applications necessitate the establishment of clear and
consistent sample collection and processing methodologies
as one of the initial stages in assay development. The effects
98
kDa
98
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49
38 38
28
17
14
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fluid:
123 123
PF GDF
ab
Figure 2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) protein fractionation of precipitated (a) gastroduodenal and (b) pancreatic
ﬂuid. Coomassie-stained SDS-PAGE images of proteins extracted from gastro-
duodenal and pancreatic ﬂuid each from three patients. GDF, gastroduodenal ﬂuid;
PF, pancreatic ﬂuid.
GDF PF
(total: 285) (total: 473)
46 239 234
Figure3 ComparingproteinsidentiﬁedbyGeLC-MS/MSingastroduodenaland
pancreatic ﬂuid. Qualitative analysis identiﬁed proteins exclusive to gastroduodenal
and pancreatic ﬂuid. GDF, gastroduodenal ﬂuid; PF, pancreatic ﬂuid.
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duodenal and pancreatic ﬂuids as a result of the inherent high
concentration of active proteolytic enzymes. Previously, we
have made efforts to standardize sample handling of these
two ePFT-collected ﬂuids.
14–16 Signiﬁcant changes in the
proteomic proﬁle may also be introduced during sample
preparation if no consistent methodology is used. In the
development of diagnostic and prognostic biomarkers of
disease, these procedural artifacts may obscure a potentially
signiﬁcant result or be more likely to identify false positive
biomarkers.
To ensure high sample quality, we are particularly careful
that our ePFT-collected samples are immediately placed on
iceinchilledtubesfollowingcollection,promptlycentrifugedat
41C toremoveparticulates, andimmediately frozen at 801C
for future analysis. Frozen samples are thawed on ice before
desalting and protease inactivation via the precipitation. We
have shown previously that protein degradation of ePFT-
collected pancreatic ﬂuid is prominent after as little as 30min
at room temperature.
16
Several proteases and protease inhibitors are found
exclusively in gastroduodenal ﬂuid. One such protein,
pepsinogen is the precursor of pepsin, an abundant protease
secreted by the chief cells in the stomach. The cystatin class
of protease inhibitors, speciﬁcally cystatins A, D, SA, and SN,
is also identiﬁed exclusively in gastroduodenal ﬂuid. Cystatins
mainly inhibit peptidases belonging to peptidase families C1
(papain family) and C13 (legumain family).
32,33 Signiﬁcantly,
cystatin SN has recently been implicated in gastric cancer.
34
Gastricsin, a precursor of gastrin (aspartic protease), has
been determined to be enriched in gastroduodenal ﬂuid.
Gastricsin is produced in the stomach and is a major
component of the gastric mucosa. Elevated levels of gastrin
have been associated previously with susceptibility to gastric
cancer.
35,36
Similarly, several proteins were identiﬁed exclusively in our
pancreatic ﬂuid analysis. Among them are elastase-2B and
neprilysin. Elastase-2B has been identiﬁed previously in
pancreatic ﬂuid from chronic pancreatitis patients, but not
from pancreatic cancer and thus is a potential biomarker for
differentiating the two diseases.
37 In addition, neprilysin, also
known as CD10 or MME, is a metalloprotease that has been
associated previously with a variety of signaling peptide
cascadesandcancer.
38,39Wealsoidentiﬁedseveralcommon
pancreatic protease enzymes enriched in pancreatic ﬂuid
including: aminopeptidase N, chymotrypsin C, elastase-3A,
trypsin 1, and carboxypeptidase A1.
40 Serpins A11, B4, and
D1 are among the protease inhibitor proteins that are
identiﬁed exclusively in pancreatic ﬂuid, while serpin B6 is
enriched in pancreatic ﬂuid. This ﬁnding is expected as
serpins, a group of similarly structured proteins, are the
predominant class of protease inhibitors in pancreatic ﬂuid.
The members of the extracellularly secreted serpin family
have various functions, including involvement in the proteo-
lytic cascades central to inﬂammatory responses, blood
clotting, and tissue remodeling.
41 Although serpin A11 is
uncharacterized, serpin B4 is an inhibitor of cathepsin G and
chymase, serpin B4 is an inhibitor of cathepsin G, while serpin
D1 is a thrombin inhibitor.
42–44 We suspect this family of
protease inhibitors may have a large role in pancreatic
disease, and as such, merits further investigation.
Itisworthnoting,however,thatwedeemcertainproteinsas
‘‘exclusive’’ to a particular cohort, as they were not detected
with the current methodology and technology. In fact such
‘‘exclusive’’ proteins may be present in the other ﬂuid, albeit at
a substantially (several orders of magnitude) lower concen-
tration, due to being below the threshold of detection. Using
Table 2 Summary of identiﬁed proteins
Number of identiﬁed proteins
Sample Patient # Total Non-redundant
in sample
Exclusive to
particular ﬂuid
Statistically signiﬁcant
enrichment
a
Total differentially
detected
1 244
GDF 2 225 285 46 41 87
3 206
1 350
PF 2 351 473 234 67 301
3 437
GDF, gastroduodenal ﬂuid; IPI #, international protein index number; PF, pancreatic ﬂuid.
aStatistically signiﬁcant Bayes factor 4 10. Total differentially detected¼exclusive to particular ﬂuid + statistically signiﬁcant enrichment.
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auxiliary transport
binding
catalytic
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PF
GDF
electron carrier
enzyme regulator
molecular transducer
motor
structural molecule
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Figure 4 Gene ontology (GO) analysis revealed the molecular function
of proteins that were exclusive to or enriched in gastroduodenal or pancreatic
ﬂuid. Using Scaffold3, the two sets of differentially detected proteins were used for
GO classiﬁcation of molecular function. GDF, gastroduodenal ﬂuid; PF, pancreatic
ﬂuid.
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tration and instrumental sampling, it is not possible to
identify every protein present in a sample. In the future, with
improvements in depth of proteome coverage, it may be
possible to detect particular proteins—which have been
currently deemed ‘‘exclusive’’ to one cohort—in both ﬂuids.
However, as we are using quantitative techniques, it is
expected that such proteins would remain statistically more
abundant in the ‘‘exclusive’’ ﬂuid.
Although both gastroduodenal and pancreatic ﬂuids are
secreted from the upper gastrointestinal tract and can be
collected using the ePFT method, our data emphasize these
ﬂuids require different sample preparation techniques for
optimal GeLC-MS/MS analysis. The argument could be
made that the differences in protein detection patterns that
we observed are a result of the different precipitation
techniques used. However, our aim is to compare the ﬂuid
samples prepared using the technique best suited for
maximum protein yield in each ﬂuid type. In essence, the
presence of the proteolytic enzymes in the ﬂuids being
analyzed precludes the use of identical precipitation condi-
tions in this study.
We have shown that acidiﬁcation of gastroduodenal ﬂuid
(e.g., by TCA) does not prevent protein degradation.
14 In fact,
concordant with known gastric physiology, the conversion of
inactive pepsinogen to the protease pepsin is typically
activated by the acidic pH.
45 Thus, acidic TCA-based protein
precipitation is counterproductive in the case of gastroduo-
denal ﬂuid, as it may activate gastric protease precursors.
Acetone is chosen as our precipitation reagent for gastro-
duodenal ﬂuid as little protein degradation is evident and
protein yield was maximized when compared with other
precipitation methods, as shown previously.
14 Similarly, using
SDS-PAGE analysis we have determined in a prior study that
the highest amount of protein could be extracted from
pancreatic ﬂuid using TCA.
16 TCA precipitation has the
Table 3 Proteases exclusive to gastroduodenal ﬂuid and pancreatic ﬂuid
Proteases IPI # Spectral counts
Exclusive to gastroduodenal ﬂuid GDF1 GDF2 GDF3
Cathepsin E IPI 00025062 9 5 8
Leukocyte elastase IPI 00027769 3 4 4
Pepsinogen 3 IPI 00736755 175 196 185
Transmembrane protease, serine 11D IPI 00003542 3 2 7
Exclusive to pancreatic ﬂuid PF1 PF2 PF3
Chymotrypsin-like protease CTRL-1 IPI 00643847 11 11 6
Dipeptidyl peptidase 4 IPI 00018953 2 11 4
Elastase-2B IPI 00027723 64 61 53
Glutamate carboxypeptidase 2 IPI 00028514 1 1 1
Glutamyl aminopeptidase IPI 00014375 3 4 4
MEP1A protein IPI 00004372 10 7 5
Meprin A beta IPI 00178015 6 3 4
Neprilysin IPI 00247063 15 19 11
Plasminogen IPI 00019580 4 4 3
Prostasin IPI 00329538 2 3 3
Protein disulﬁde-isomerase A3 IPI 00025252 0 1 3
Similar to Complement factor B IPI 00019591 0 3 6
Xaa-Pro aminopeptidase 2 IPI 00439344 4 2 5
GDF, gastroduodenal ﬂuid; IPI #, international protein index number; PF, pancreatic ﬂuid.
Table 4 Proteases of statistically signiﬁcant enrichment in gastroduodenal ﬂuid and pancreatic ﬂuid
Proteases IPI # Spectral counts Bayes factor Fold change
GDF1 GDF2 GDF3 PF1 PF2 PF3
Higher abundance in gastroduodenal ﬂuid
Gastricsin IPI 00022213 86 103 94 4 6 1 3.9E+08 26.58
Kallikrein-1 IPI 00304808 11 17 5 3 2 3 3.4E+01 3.87
Higher abundance in pancreatic ﬂuid
Aminopeptidase N IPI 00221224 16 12 7 91 108 90 3.0E+07 7.56
Protease serine 4 isoform B IPI 00385250 8 7 13 48 76 50 7.4E+04 6.18
Chymotrypsin B2 IPI 00515087 48 65 26 149 153 136 1.6E+05 3.24
Chymotrypsin-C IPI 00018553 16 24 8 60 38 33 1.8E+02 2.76
Elastase-2A IPI 00027722 75 107 43 188 222 170 1.6E+04 2.50
Carboxypeptidase A1 IPI 00009823 142 162 93 255 320 340 7.9E+03 2.25
Trypsin-1 IPI 00011694 82 99 76 143 182 164 1.3E+04 1.91
Elastase-3A IPI 00295663 49 80 38 128 88 88 3.1E+01 1.83
PRSS1 protein IPI 00815665 71 73 76 91 149 138 1.0E+02 1.69
GDF, gastroduodenal ﬂuid; IPI #, international protein index number; PF, pancreatic ﬂuid.
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simultaneously acidifying it, thereby inactivating pancreatic
proteases via denaturation. In addition, lower molecular
weight band smears, indicating proteolysis, are minimized
when TCA is used compared with the other protein extraction
strategies.
16 In the case of pancreatic ﬂuid (generally pH
8-8.5), the decrease in pH resulting from TCA addition
successfully precipitates proteins and inhibits the activity of
pancreatic proteases. As mentioned above, this effect is in
contrast to gastroduodenal ﬂuid, in which gastric enzymes, such
as gastrin and pepsin, are active at very acidic pH in which the
addition of TCA to gastroduodenal ﬂuid promotes proteolysis.
We aim to overcome several potential limitations to our
methodology in future studies. We acknowledge that the
secretin-stimulated ePFT-collected gastroduodenal and
pancreatic ﬂuid samples are admixtures of several upper
gastrointestinal ﬂuids. Regarding the presence of pancreatic
proteins in gastroduodenal ﬂuid, such an admixture is an
expected result of basal pancreatic secretions before secretin
stimulation during ePFT. However, as we have shown, the
majority of the proteins identiﬁed in gastroduodenal ﬂuid are
from the stomach and the duodenum. Likewise, the presence
of a nominal amount of gastroduodenal proteins in pancreatic
ﬂuid is to be expected, but the contribution of this ﬂuid is
minimized by ﬂuid aspiration in the duodenum before ePFT.
Moreover, any residual gastroduodenal ﬂuid proteins are
subsequently diluted by the protein-rich secretin-stimulated
pancreatic secretions, particularly as the sample for proteo-
mic analysis is collected 30min post-secretin stimulation.
Furthermore, duodenal protein secretion is minimal, and
potential gastric ﬂuid efﬂux isdecreased by placing the patient
in the left lateral decubitus position. As we show herein, such
differences are apparent when comparing gastroduodenal
and pancreatic ﬂuid both visually by the SDS-PAGE protein
banding pattern proﬁle and by qualitative and quantitative
mass spectrometry analysis.
In conclusion, using ePFT collection coupled with mass
spectrometry, we have identiﬁed proteins which are differen-
tially detected in either gastroduodenal or pancreatic ﬂuid.
These data obtained using GeLC-MS/MS techniques provide
further evidence supporting the feasibility of using ePFT-
collected ﬂuid to study speciﬁc diseases of the upper
gastrointestinal tract. As such, our research team is currently
performing a study searching for biomarkers of chronic
pancreatitis via a comparative proteomic analysis of secre-
tin-stimulated, ePFT-collected pancreatic ﬂuid. We aim to
identify biomarkers that can be traced back to physiological
events of the pancreas. Such a study is supported by the
premise that the majority of identiﬁed proteins are indeed of
pancreatic origin, as we illustrate herein. In addition, other
studies may be designed to target the role of these proteases
and protease inhibitors—such as cystatins and serpins—in
gastroduodenal and pancreatic diseases. Further elucidation
ofdifferences inthe proteomes ofeach ePFT-collected ﬂuid in
diseased and non-diseased patients, may provide a better
understanding of the molecular mechanisms leading to the
onset and progression of upper gastrointestinal disease. In
summary, we have shown that there is indeed a unique
proteome in the ePFT-collected secretin-stimulated pancrea-
tic ﬂuid when compared with gastroduodenal ﬂuid. Future
studiesmayexploitsuchePFT-basedﬂuidcollectionstostudy
particular diseases of the upper gastroduodenal tract.
Table 5 Protease inhibitors exclusive to gastroduodenal ﬂuid and pancreatic
ﬂuid
Protease inhibitor proteins IPI # Spectral counts
Exclusive to gastroduodenal ﬂuid GDF1 GDF2 GDF3
Alpha-2-macroglobulin-like
protein 1
IPI 00419215 10 10 5
Cystatin-A IPI 00032325 13 7 15
Cystatin-D IPI 00002851 0 5 2
Cystatin-SA IPI 00013382 9 14 7
Cystatin-SN IPI 00305477 16 23 3
Lipocalin-1 IPI 00009650 86 122 55
Uteroglobin IPI 00006705 4 3 0
Exclusive to pancreatic ﬂuid PF1 PF2 PF3
Alpha-2-antiplasmin IPI 00879231 1 1 1
Annexin A5 IPI 00329801 3 1 3
Heat shock protein HSP 90-alpha IPI 00784295 0 1 4
Histidine-rich glycoprotein IPI 00022371 1 2 15
Inter-alpha-trypsin inhibitor H1 IPI 00292530 1 1 3
Isoform HMW of Kininogen-1 IPI 00032328 0 1 4
Kallistatin IPI 00328609 1 0 1
Serpin A11 IPI 00333828 0 1 0
Serpin B4 IPI 00010303 0 1 37
Serpin D1 IPI 00292950 1 0 3
Thyroxine-binding globulin IPI 00292946 1 1 1
GDF, gastroduodenal ﬂuid; HMW, high molecular weight; IPI #, international
protein index number; PF, pancreatic ﬂuid.
Table 6 Protease inhibitors of statistically signiﬁcant enrichment in gastroduodenal ﬂuid and pancreatic ﬂuid
Protease inhibitor proteins IPI # Spectral counts Bayes factor Fold change
GDF1 GDF2 GDF3 PF1 PF2 PF3
Higher abundance in gastroduodenal ﬂuid
Annexin A1 IPI 00218918 25 46 3 0 0 4 1.8E+01 15.26
Antileukoproteinase IPI 00008580 22 19 8 1 2 0 2.9E+03 13.28
Leukocyte elastase inhibitor IPI 00027444 10 27 17 8 8 8 8.3E+00 2.13
Higher abundance in pancreatic ﬂuid
Annexin A4 IPI 00872780 0 1 0 6 10 15 4.4E+02 19.39
Alpha-2-macroglobulin IPI 00478003 9 9 5 161 145 169 1.0E+10 16.83
Antithrombin-III IPI 00032179 0 1 8 9 13 23 3.1E+01 5.38
Serpin B6 IPI 00749398 4 2 2 11 6 14 3.2E+01 3.77
Annexin A2 isoform 1 IPI 00418169 9 10 5 18 11 32 1.1E+01 2.34
GDF, gastroduodenal ﬂuid; IPI #, international protein index number; PF, pancreatic ﬂuid.
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|ePFT allows for the safe collection of gastroduodenal
and pancreatic ﬂuid from the duodenum.
|ePFT-collected secretions are rich in proteins.
|Mass spectrometry-based proteomics can be used
to identify proteins from body ﬂuids.
WHAT IS NEW HERE
|Gastroduodenal and pancreatic ﬂuid can be
sequentially collected from the same patient.
|Proteins can be readily extracted and identiﬁed from
gastroduodenal and pancreatic ﬂuid by ﬂuid-speciﬁc
chemical precipitation methods.
|Proteases and enzyme regulators comprise the major
molecular functions of the identiﬁed proteins for both
gastroduodenal and pancreatic ﬂuid.
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